A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00943553

Recruitment Status : Withdrawn (Terminated by Sponsor)

First Posted : July 22, 2009

Last Update Posted : April 13, 2015

Sponsor:

Information provided by (Responsible Party):

Eisai Inc.

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

Study was withdrawn before participants were enrolled.

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Withdrawn
Actual Primary Completion Date :	August 2011
Study Completion Date :	No date given

To Top